Mielóma multiplex: vizsgálatok itt: Tajvan
19 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
- Where
- Changhua, Hualien City, Kaohsiung City, Taichung, Tainan, Taipei, Taoyuan
- Életkor
- 18 év and over
- People
- 410 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT05730036 · EU 2022-501396-62-00 - 3. fázisTaking peopleA Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
- Where
- Kaohsiung City, Taichung, Taipei, Taoyuan
- Életkor
- 18 év and over
- People
- 915 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT07222761 · EU 2024-519504-27-00 - 3. fázisTaking peopleA Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Where
- Taichung, Taipei, Taipei City
- Életkor
- 18 év and over
- People
- 440 worldwide
- Run by
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06615479 · EU 2024-515279-37-00 - 3. fázisTaking peopleA Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- Where
- Taichung, Taipei, Taoyuan
- Életkor
- 18 év and over
- People
- 1060 worldwide
- Run by
- Pfizer
See details and how to joinNCT05623020 · EU 2024-514139-50-00 - 3. fázisTaking peopleA Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
- Where
- Taipei, Taoyuan
- Életkor
- 18 év to 130 év
- People
- 750 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07735637 - 2. fázisCsak meghívásosInternational Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
- Where
- Taichung
- Életkor
- 18 év and over
- People
- 70 worldwide
- Run by
- Sanofi
See details and how to joinNCT05669989 - 3. fázisTaking peopleA Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Where
- Taipei
- Életkor
- 18 év and over
- People
- 508 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07391657 - 3. fázisTaking peopleA Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Kaohsiung City, Taichung, Tainan, Taipei
- Életkor
- 18 év and over
- People
- 700 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07518186 - 1/2. fázisTaking peopleStudy of HuL001 in Relapsed/Refractory Multiple Myeloma Patients
- Where
- Taipei
- Életkor
- 18 év and over
- People
- 21
- Run by
- HuniLife Biotechnology, Inc.
See details and how to joinNCT07210047 - 3. fázisTaking peopleA Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- Where
- Kaohsiung City, Taichung, Tainan, Taipei
- Életkor
- 18 év and over
- People
- 893 worldwide
- Run by
- Pfizer
See details and how to joinNCT05020236 · EU 2023-509208-14-00 - 3. fázisTaking peopleMagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Where
- Taichung
- Életkor
- 18 év and over
- People
- 492 worldwide
- Run by
- Pfizer
See details and how to joinNCT06152575 · EU 2023-507871-23-00 - 1/2. fázisTaking peopleA Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- Where
- Changhua, Kaohsiung City, Taipei
- Életkor
- 18 év and over
- People
- 123 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT05714839 · EU 2022-501941-63-00 - 1/2. fázisTaking peopleA Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
- Where
- Taipei
- Életkor
- 18 év and over
- People
- 220 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06292780 · EU 2023-507809-34-00 - 3. fázisTaking peopleStudy of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Where
- Taipei, Taoyuan
- Életkor
- 18 év and over
- People
- 750 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07764978 - No phaseTaking peopleDevelopment and Dissemination of Exercise Prescription and Intervention for Cancer Populations
- Where
- Kaohsiung
- Életkor
- 18 év to 80 év
- People
- 150
- Run by
- Kaohsiung Medical University Chung-Ho Memorial Hospital
See details and how to joinNCT07751783 - 3. fázisNot yet taking people in TajvanA Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
- Where
- Kaohsiung City
- Életkor
- 18 év and over
- People
- 520 worldwide
- Run by
- AbbVie
See details and how to joinNCT07728188 · EU 2026-525596-11-00 - 4. fázisTaking peopleElranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
- Where
- Taipei
- Életkor
- 18 év and over
- People
- 80 worldwide
- Run by
- Pfizer
See details and how to joinNCT06057402 · EU 2023-505200-33-00 - 3. fázisTaking peopleA Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- Where
- Kaohsiung City, Taichung, Tainan, Taipei, Taoyuan
- Életkor
- 18 év and over
- People
- 520 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT06679101 · EU 2024-516030-35-00 - 1/2. fázisTaking peopleA Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Where
- Taichung, Tainan, Taipei
- Életkor
- 12 év and over
- People
- 606 worldwide
- Run by
- Sumitomo Pharma America, Inc.
See details and how to joinNCT04988555